Navigation Links
Spherix Incorporated to Present at the Rodman & Renshaw 13th Annual Healthcare Conference
Date:9/6/2011

BETHESDA, Md., Sept. 6, 2011 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX) -- an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies -- today announced that Dr. Claire Kruger, Chief Executive Officer, and Dr. Robert Lodder, President, will be presenting a corporate overview at the Rodman & Renshaw 13th Annual Healthcare Conference at 3:40 p.m. on September 12, 2011, in Metropolitan West of the Waldorf Astoria in New York.  The conference will be held from September 11-13, 2011.

A live audio and archived webcast of Spherix's presentation will be available through the Investor Relations section of the Company's website.

About Spherix

Spherix Incorporated was launched in 1967 as a scientific research company under the name Biospherics Research.  The Company now leverages its scientific and technical expertise and experience through its two subsidiaries -- Biospherics Incorporated and Spherix Consulting, Inc.  Biospherics is dedicated to developing and licensing/marketing proprietary therapeutic products for treatment of diabetes, metabolic syndrome and atherosclerosis.  Biospherics is actively seeking a pharmaceutical partner to continue the development of its Phase 3 compound for the treatment of diabetes, D-tagatose, while exploring new drugs and combinations for treatment of high triglycerides, a risk factor for atherosclerosis, myocardial infarction, and stroke.  Spherix's Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, med
'/>"/>

SOURCE Spherix Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Spherix Announces Second Quarter Financial Results
2. Spherix Drug Candidate SPX-106 Shows Statistically Significant Reductions in Serum Triglycerides in Preclinical Testing
3. Spherix Announces Registered Direct Offering of $2.77 Million
4. Spherix Announces Post-Hoc Analysis of Phase 3 Trial With D-Tagatose in Diabetes
5. Spherix Announces Third Quarter 2010 Financial Results
6. Spherix Awarded Grant from U.S. Government Under the Patient Protection and Affordable Care Act
7. Spherix Announces Institutional Investors Purchase $5.25 Million of Convertible Preferred Stock and Warrants
8. Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes
9. Spherix to Present at Annual OneMedPlace Finance Forum and at EBD Biotech Showcase in San Francisco
10. Spherix Reports Third Quarter 2009 Earnings
11. Spherix Announces Positive Phase 2 Study Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... PINE BROOK, N.J. , Sept. 22, 2014 ... developing antibody therapies to treat infectious disease, today ... adult volunteer safety studies of obiltoxaximab (ETI-204). Obiltoxaximab ... of inhalational anthrax and data from these studies ... when administered intravenously (IV) at the intended therapeutic ...
(Date:9/22/2014)...  AVT, Inc. (OTC Markets: AVTC) ( www.autoretail.com ), ... machines, announced today that they are starting production of ... unit is designed for placement inside optical shops and ... statistics, there are over 20,000 optical stores in ... world,s first automated kiosk dedicated to cleaning and sanitizing ...
(Date:9/22/2014)... , Sept. 22, 2014  Olympus, a ... solutions for medical and surgical procedures, among other ... deal with Munich -based Brainlab ... ® Navigation. This agreement applies to the ... cross-disciplinary U.S. sales and all distribution outside the ...
Breaking Medicine Technology:Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6Opticwash Pro Enables Optical Retailers to Generate New Revenues and Customer Traffic through a Unique Eyeglass Cleaning System 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 4
... Pevion Biotech AG today announced ... therapeutic Candida vaccine PEV7, demonstrating the generation of specific ... Furthermore, the results again confirm the capability of Pevion,s ... long-lasting immunity in humans against otherwise weak antigens ...
... Mass. and MIAMI, Jan. 16, 2012 Boston Scientific ... endpoint data from its ORION trial, demonstrating excellent outcomes ... patients with iliac artery disease, a form of peripheral ... insufficient blood flow.  Results were presented today by Daniel ...
Cached Medicine Technology:Pevion's Therapeutic Candida Vaccine Generates Functional B Cell Memory in all Vaccinees 2Pevion's Therapeutic Candida Vaccine Generates Functional B Cell Memory in all Vaccinees 3Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial 2Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial 3Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial 4Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial 5
(Date:9/23/2014)... Angeles, CA (PRWEB) September 23, 2014 ... power score of 3.7 out of 5, indicating ... fixed or portable and range from basic household ... of reading gas concentrations in parts per million. ... them the choice of many suppliers, especially amongst ...
(Date:9/23/2014)... NJ (PRWEB) September 23, 2014 With ... cease the sale of all tobacco products, retail chains ... products and services to patients, customers, and shoppers. In ... the stakeholders of retail pharmacy healthcare to share their ... you need to know to coordinate care with other ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Dallas-based luxury linen ... appointment of Leslie Eades as vice president of product development. ... as well as the primary lead on global sourcing for ... head of both the product development group and sourcing group ... team. , Eades notes, "Peacock Alley is a brand ...
(Date:9/22/2014)... FL (PRWEB) September 23, 2014 ... wrinkles. A Sublime Beauty® cream helps to relax ... boost collagen levels and hydrate beautifully. , "Our ... a multi-tasker for aging skin," says Kathy Heshelow, ... as the natural botox, wrinkles are relaxed while ...
(Date:9/22/2014)... September 23, 2014 Recently, BamboofloorChina.com, an ... new range of solid bamboo floors . According ... are now provided at discounted rates, up to 30 ... until September 30. , BamboofloorChina.com is ... solid bamboo floors are made according to the newest ...
Breaking Medicine News(10 mins):Health News:Gas Detectors Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Gas Detectors Procurement Category Market Research Report Now Available from IBISWorld 3Health News:Retail Pharmacies at the Forefront of Primary Care Innovation 2Health News:Luxury Linen Purveyor Peacock Alley Announces New Vice President of Product Development 2Health News:How to Reduce Wrinkles and Improve Aging Skin from Sublime Beauty®; One Day Sale on Now 2Health News:Cheap Solid Bamboo Floors From Outstanding Online Supplier BamboofloorChina.com 2
... may soon impact the quality of patient care for ... report. ,Without intervention, the number of allergy-immunology ... demand will increase by 35 percent over the next ... ,The decline in the number of qualified allergists-immunologists ...
... today warned consumers could be seriously misled by proposed new ... to Food Standards Australia and New Zealand (FSANZ), Dr Yong ... confuse consumers and may even contribute to unhealthy diets. ... on labels to encourage consumers to buy their products, Dr ...
... insensitive caption for the picture of an abandoned baby in Melbourne ... left in a cardboard box kept by a Japanese hospital for ... Jikei Hospital in the southern city of Kumamoto to discourage abortions ... ,A small hatch on the side of the hospital has ...
... This high degree of trust and confidence in doctors reflects ... survey reflects the immense efforts from doctors to improve ... the financial pressures placed upon the health service. ... this survey, the majority of respondents have answered that doctors ...
... University of Illinois food science and human nutrition professor ... a persons diet , and safe alternatives to hormone-replacement ... spent a decade evaluating the health effects of isoflavones, ... in soy. Much of his work has focused on ...
... of Wisconsin-Madison have designed a powerful analytical tool capable of ... moving proteins in mid-fold and see the shapes of intermediate ... is that the first applications of the technique offer a ... is implicated in type II diabetes. ,Pancreatic ...
Cached Medicine News:Health News:America on Brink of Allergy Crisis 2Health News:Three-year-old Abandoned in Box Meant for Unwanted Babies in Japan 2Health News:Soy Products a Double-edged Sword for Breast Cancer 2Health News:Soy Products a Double-edged Sword for Breast Cancer 3Health News:New Analytical Tool to Unravel the Cause of Diabetes 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: